phenyl (benzyloxy-dimethylglycinyl)phosphorochloridate | 840506-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl (benzyloxy-dimethylglycinyl)phosphorochloridate
• 英文别名: phenyl(benzyloxy-L-dimethylglycine)phosphorochloridate；phenyl (benzoxydimethylglycinyl) phosphorochloridate；benzyl 2-((chloro(phenoxy)phosphoryl)amino)-2-methylpropanoate；phenyl(benzoxydimethylglycinyl)phosphochloridate；phenyl [(1-benzyloxycarbonyl-1-methylethyl)amino]phosphorochloridate；2-phenyl-(benzyloxy-2-amino-2-methylpropanoate)phosphorochloridate；phenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate；Benzyl 2-[[chloro(phenoxy)phosphoryl]amino]-2-methylpropanoate
• CAS: 840506-42-5
• 化学式: C₁₇H₁₉ClNO₄P
• 分子量: 367.769
• InChiKey: XAQUBJXQYCBOKG-UHFFFAOYSA-N

物化性质

• 沸点：
  464.1±47.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  phenyl (benzyloxy-dimethylglycinyl)phosphorochloridate 在 甲酸 、 叔丁基氯化镁 作用下， 以 四氢呋喃 为溶剂， 反应 21.25h， 生成 2-{[(2R,3S,4R,5R)-2-Azido-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-2-methyl-propionic acid benzyl ester
  参考文献：
  名称：

  Application of the Phosphoramidate ProTide Approach to 4‘-Azidouridine Confers Sub-micromolar Potency versus Hepatitis C Virus on an Inactive Nucleoside

  摘要：

  We report the application of our phosphoramidate ProTide technology to the ribonucleoside analogue 4'-azidouridine to generate novel antiviral agents for the inhibition of hepatitis C virus (HCV). 4'-Azidouridine did not inhibit HCV, although 4'-azidocytidine was a potent inhibitor of HCV replication under similar assay conditions. However 4'-azidouridine triphosphate was a potent inhibitor of RNA synthesis by HCV polymerase, raising the question as to whether our phosphoramidate ProTide approach could effectively deliver 4'-azidouridine monophosphate to HCV replicon cells and unleash the antiviral potential of the triphosphate. Twenty-two phosphoramidates were prepared, including variations in the aryl, ester, and amino acid regions. A number of compounds showed sub-micromolar inhibition of HCV in cell culture without detectable cytotoxicity. These results confirm that phosphoramidate ProTides can deliver monophosphates of ribonucleoside analogues and suggest a potential path to the generation of novel antiviral agents against HCV infection. The generic message is that ProTide synthesis from inactive parent nucleosides may be a warranted drug discovery strategy.

  DOI：

  10.1021/jm0613370
• 作为产物：
  描述：

  α-Aminoisobutyric acid benzyl ester p-toluenesulfonate 、 二氯磷酸苯酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到phenyl (benzyloxy-dimethylglycinyl)phosphorochloridate
  参考文献：
  名称：

  The Application of Phosphoramidate Protide Technology to Acyclovir Confers Anti-HIV Inhibition

  摘要：

  Recently, it has been reported that phosphorylated acyclovir (ACV) inhibits human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in a cell-free system. To deliver phosphorylated ACV inside cells, we designed ACV monophosphorylated derivatives using ProTide technology. We found that the L-alanine derived ProTides show anti-HIV activity at noncytotoxic concentrations; ester and aryl variation was tolerated, ACV ProTides with other amino acids, other than L-phenylalanine, showed no detectable activity against HIV in cell culture. The inhibitory activity of the prodrugs against herpes simplex virus (HSV) types-1 and -2 and thymidine kinase-deficient HSV-1 revealed different structure-activity relationships but was again consistent with successful nucleoside kinase bypass. Enzymatic and molecular modeling studies have been performed in order to better understand the antiviral behavior of these compounds. ProTides showing diminished carboxypeptidase lability translated to poor anti-HIV agents and vice versa, so the assay became predictive.

  DOI：

  10.1021/jm9007856

文献信息

• Antiviral phosphoramidates
  申请人：Klumpp Klaus

  公开号：US20070042988A1

  公开（公告）日：2007-02-22

  The invention provides novel nucleoside compounds of formula I wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , R 8a , R 9 and R 10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,

  该发明提供了一种新颖的核苷类化合物，其化学式为I，其中R1、R2a、R2b、R3、R4、R5、R6、R8a、R9和R10如本文所定义，这些化合物对治疗由丙型肝炎病毒（HCV）介导的疾病是有用的。该发明还提供了使用化合物I的方法进行治疗或预防HCV介导的疾病，以及包含这些化合物的药物组合物。
• [EN] SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS<br/>[FR] SELS DE PHOSPHORAMIDATE DIPHOSPHATE DE NUCLÉOSIDES UTILISÉS EN TANT QUE COMPOSÉS ANTICANCÉREUX
  申请人：NUCANA PLC

  公开号：WO2019110991A1

  公开（公告）日：2019-06-13

  The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.

  本发明涉及包括核苷药物的二磷酸磷酰胺盐化合物，例如克洛法滨。这些化合物在癌症治疗中，如白血病治疗中具有用途。
• ProTides of N-(3-(5-(2′-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents
  作者：Christopher McGuigan、Marco Derudas、Blanka Gonczy、Karen Hinsinger、Sahar Kandil、Fabrizio Pertusati、Michaela Serpi、Robert Snoeck、Graciela Andrei、Jan Balzarini、Timothy D. McHugh、Arundhati Maitra、Ernest Akorli、Dimitrios Evangelopoulos、Sanjib Bhakta

  DOI：10.1016/j.bmc.2014.02.056

  日期：2014.5

  flavin-dependent thymidylate synthase X (ThyX), rare in eukaryotes and completely absent in humans, is crucial in the metabolism of thymidine (a DNA precursor) in many microorganisms including several human pathogens. Conserved in mycobacteria, including Mycobacterium leprae, and Mycobacterium tuberculosis, it represents a prospective anti-mycobacterial therapeutic target. In a M. tuberculosis ThyX-enzyme

  黄素依赖性胸苷酸合酶 X (ThyX) 在真核生物中很少见，在人类中完全不存在，它在许多微生物（包括几种人类病原体）中的胸苷（一种 DNA 前体）代谢中至关重要。它保存在分枝杆菌中，包括麻风分枝杆菌和结核分枝杆菌，代表了一种前瞻性的抗分枝杆菌治疗靶点。在结核分枝杆菌ThyX 酶抑制试验中，N-(3-(5-(2'-deoxyuridine-5'-phosphate))prop-2-ynyl)octanamide 据报道是最有效和选择性的 5-取代 2'-脱氧尿苷单磷酸类似物。在这项研究中，我们使用 ProTide 技术掩盖了该化合物磷酸盐部分的两个电荷，以增加其亲脂性，然后允许渗透通过复杂的分枝杆菌细胞壁。化学合成了一系列N -(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide 氨基磷酸酯，并评估了它们作为潜在抗结核药的生物活性。除分枝杆菌外，几种 DNA
• Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides
  作者：Marco Derudas、Christophe Vanpouille、Davide Carta、Sonia Zicari、Graciela Andrei、Robert Snoeck、Andrea Brancale、Leonid Margolis、Jan Balzarini、Christopher McGuigan

  DOI：10.1021/acs.jmedchem.7b01009

  日期：2017.9.28

  anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) phosphate prodrugs, we herein report the ProTide approach applied to a series of acyclic nucleosides aimed at the identification of novel and selective antiviral, in particular anti-HIV agents. Acyclic nucleoside analogues used in this study were identified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate

  根据我们对无环鸟苷（ACV）磷酸盐前药的抗人免疫缺陷病毒（HIV）活性的发现，我们在此报告了ProTide方法应用于一系列无环核苷的用途，旨在鉴定新型和选择性抗病毒剂，特别是抗HIV代理商。本研究中使用的无环核苷类似物通过使用HIV逆转录酶（RT），腺苷酸/鸟苷酸激酶和人DNA聚合酶γ的虚拟筛选进行鉴定。总共合成了39种新的磷酸盐前药，并针对HIV-1（体外和离体人类扁桃体组织系统）和人类疱疹病毒进行了评估。几种ProTide化合物在低微摩尔范围内显示出对HIV-1的显着效力，而母体核苷则无效。另外，观察到明显抑制疱疹病毒复制。
• DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS
  申请人：SOFIA MICHAEL JOSEPH

  公开号：US20090099136A1

  公开（公告）日：2009-04-16

  Disclosed are dioxolane thymine phosphoramidate compounds, compositions, and methods for using dioxolane thymine phosphoramidate compounds and compositions to treat viral infections, such as HIV infections.

  本发明涉及二氧杂环己烷胸腺嘧啶磷酰胺化合物、组合物以及使用二氧杂环己烷胸腺嘧啶磷酰胺化合物和组合物治疗病毒感染，例如HIV感染的方法。